Herui Gene was invited to participate in IBIWS and released the latest research results of early screening of multiple cancers

Shanghai, October 12, 2021/PRNewswire/ - October 12, 2021, during the first "Shanghai International Biopharmaceutical Industry Week (IBIWS)", as the global genetic testing industry and cancer early screening track representative company, Herui Gene was invited to attend the "2021 Future Medical Industry Summit", one of the important events of the Industry Week organized by the largest public fund management company in China, E Fund.

Relying on the excellent performance and general characteristics of the platform-based underlying technology HIFI, following the major breakthrough of "from 0 to 1" in the early screening of liver cancer, Herui Gene has once again taken a solid step "from one to many": one test achieves six major China For the early screening of high-risk cancers, all detection indicators have reached or exceeded the international advanced level

2021 Shanghai International Biopharmaceutical Industry Week faces the world and brings together top scholars, investment institutions and leading companies at home and abroad to comprehensively interpret the cutting-edge development trends of biomedicine and in-depth discussions on the development direction and key tracks of the biomedical industry

The latest research results of early screening of multiple cancers are released, covering 6 high-risk cancers in China

Based on HIFI, the underlying technology of Herui gene platform, one detection can achieve early screening of 6 high-risk cancers in China, including liver cancer, lung cancer, gastric cancer, colorectal cancer, esophageal cancer, and pancreatic cancer.

Zhou Jun said: "In this multi-cancer early screening study, Herui Gene specially selected lung cancer and gastrointestinal tumors as breakthrough points, precisely because they are the most threatening cancer types in China

Herui gene platform type underlying technology HIFI detection performance is excellent

The advanced nature of the research results is also reflected in the coverage of a higher proportion of early-stage patients: the overall proportion of patients with stage I and II is as high as 73%, while in the detection of stage I and II samples, the sensitivity reached 69.

Herui Gene Multi-Cancer Early Screening Covers More Early Cancer Patients

It is worth noting that, for the detection of the most challenging and most malignant pancreatic cancer, the excellent performance of Herui Gene early screening technology is verified again, the sensitivity and specificity are both above 90%, and the area under the curve (AUC) Reached 0.

Herui gene early screening technology has excellent performance in detecting pancreatic cancer

Platform-based underlying technology HIFI gradually realizes early tumor screening "from 0 to 1" and "from one to many"

As the most economical and effective strategy for malignant tumor prevention and control, early screening has highlighted its significance and value in many countries and individual cancer types around the world

In recent years, liquid biopsy technology based on genetic testing has made rapid progress, allowing more diverse and trace biomarkers to be accurately detected and widely used, including Herui Gene, including early cancer screening competitions at home and abroad.

As one of the earliest local companies to deploy early cancer screening, Herui Gene independently developed the platform-based underlying technology HIFI based on liquid biopsy, and was the first to apply it to early screening of liver cancer and lung cancer

Zhou Jun, CEO of Herui Gene, delivered a keynote speech

In this speech, Zhou Jun introduced that Herui Gene first completed the "from 0 to 1" exploration through the PreCar project.

Through this research on early screening of multiple cancers, Herui Gene has taken a more solid step "from one to many"

Driven by the two-wheel drive of population aging and economic growth, China's future demand for pharmaceutical products and services will grow rapidly

---over---

Source: Herui Gene